(S1 (S (S (NP (NN Vimentin)) (VP (VBZ is) (ADVP (RB preferentially)) (VP (VBN expressed) (PP (IN in) (NP (NP (JJ human) (NN breast) (NNS carcinomas)) (PP (IN with) (NP (NP (JJ low) (NN estrogen) (NN receptor)) (CC and) (NP (JJ high) (NN Ki-67) (NN growth) (NN fraction))))))))) (. .)))
(S1 (S (S (NP (NP (NN Vimentin) (NN expression)) (, ,) (NP (NP (NN growth) (NNS fractions)) (PRN (-LRB- -LRB-) (NP (NN GF)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NN estrogen) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN ER)) (-RRB- -RRB-))) (NNS levels))) (VP (VBD were) (VP (VBN determined) (PP (IN for) (NP (CD 90) (JJ untreated) (JJ primary) (NN breast) (NNS carcinomas)))))) (. .)))
(S1 (S (S (NP (NP (NN Coexpression)) (PP (IN of) (NP (NP (NN keratin)) (CC and) (NP (NN vimentin))))) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (NP (QP (RB approximately) (CD 20)) (NN %)) (PP (IN of) (NP (NP (DT the) (NNS tumors)) (PP (ADVP (RB regardless)) (IN of) (NP (JJ menopausal) (NN status)))))))))) (. .)))
(S1 (S (S (NP (NN Vimentin)) (VP (VBD was) (VP (VBN expressed) (ADVP (RB preferentially)) (PP (IN in) (NP (NP (NN tumor) (NNS cells)) (PP (IN of) (NP (NP (JJ high-grade) (JJ ductal) (NN breast) (NNS carcinomas)) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 15) (IN of) (CD 28)) (JJ histologic) (NN grade)) (NP (QP (CD 3) (CC vs.) (CD 0) (IN of) (CD 40)) (NNS grades) (NP (NP (CD 1)) (CC and) (NP (CD 2))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NN Vimentin) (NN expression)) (VP (VBD was) (VP (VBN found) (ADVP (RB preferentially)) (PP (IN in) (NP (NP (NNS tumors)) (PP (IN with) (NP (NP (NP (JJ high) (NN GF)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (QP (JJR greater) (IN than) (CD 15)) (NN %)) (NN Ki-67)) (ADJP (JJ positive) (PP (IN by) (NP (NN immunoperoxidase) (NN staining))))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ low) (NN ER) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (QP (JJR less) (IN than) (CD 60)) (NN fmols/mg) (NN protein)) (PP (IN by) (NP (DT a) (JJ monoclonal) (NN enzyme) (NN immunoassay)))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (S (NP (NP (CD Sixty-eight) (NN percent)) (PP (IN of) (NP (NP (NNS tumors)) (PP (IN in) (NP (DT this) (NN group)))))) (VP (VBD were) (ADJP (NN vimentin) (JJ positive)))) (CC and) (S (NP (NP (CD 88) (NN %)) (PP (IN of) (NP (DT all) (JJ vimentin-positive) (NNS tumors)))) (VP (VBP fell) (PP (IN into) (NP (DT this) (NN category)))))) (. .)))
(S1 (S (S (NP (NP (QP (JJR More) (IN than) (CD 50)) (NN %)) (PP (IN of) (NP (DT the) (NN tumor) (NNS cells)))) (VP (VBD coexpressed) (NP (NP (NN vimentin)) (CC and) (NP (NN keratin))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NN vimentin) (NN expression)) (VP (MD may) (VP (VB be) (ADJP (JJ helpful) (PP (IN in) (S (VP (VBG identifying) (NP (NP (DT a) (JJ substantial) (NN subset)) (PP (IN of) (NP (NP (JJ ER-independent) (NN breast) (NNS carcinomas)) (PP (IN with) (NP (JJ poor) (JJ prognostic) (NNS indicators))))))))))))) (. .)))
